Revive Therapeutics Ltd.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a RVVTF research report →
Price Chart
About the company
Revive Therapeutics Ltd. , a life sciences firm, specializes in the research and development of treatments for rare disorders and infectious diseases. The company’s pharmaceutical pipeline features a cannabinoid portfolio focused on rare inflammatory ailments.
- CEO
- Michael Frank
- IPO
- 2015
- Employees
- 3
- HQ
- Toronto, ON, CA
Get TickerSpark's AI analysis on RVVTF
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
- Market Cap
- $3.11M
- P/E
- -8.33
- PEG
- -0.07
- P/S
- 0.00
- P/B
- -1.08
- EV/EBITDA
- -4.20
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- 26.78%
- ROIC
- 26.77%
Latest fiscal year · YoY change
- Revenue
- $0+0.0%
- Gross Profit
- $-182+0.0%
- Op Income
- $-1,065,815
- Net Income
- $-988,824+91.0%
- EPS
- $-0.00+92.3%
- OCF Growth
- +80.1%
- FCF Growth
- +80.1%
- 52W High
- $0.06
- 52W Low
- $0.00
- 50D MA
- $0.02
- 200D MA
- $0.02
- Beta
- -1.94
- RSI (14)
- 29
- Avg Volume
- 192.13K
No earnings-call transcripts are available for RVVTF yet.
- Free Float
- 96.8%
- Shares Outstanding
- 444.61M
- Float Shares
- 430.59M
Our RVVTF coverage
Recent articles, reports, and earnings notes.
No research on RVVTF yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate RVVTF report →Revive Therapeutics to Expand Bucillamine IP and Orphan Drug Portfolio Across Medical Countermeasures and Rare Diseases
accessnewswire.com · Sep 15
Revive Therapeutics Announces Proposed Shares for Debt Settlement
accessnewswire.com · Aug 19
Revive Therapeutics Outlines Strategy to Build a Biodefence and Pandemic Preparedness Therapeutics Portfolio
accessnewswire.com · Aug 19
Revive Therapeutics Reports Grant of Options
accessnewswire.com · Aug 14
Revive Therapeutics Reports Positive Results from DRDC Bucillamine Nerve-Agent Research Study
accessnewswire.com · Aug 12
Revive Therapeutics Announces Closing of First Tranche of Non-Brokered Private Placement
accessnewswire.com · Jul 15
Revive Therapeutics Announces Proposed Private Placement
accessnewswire.com · Jun 26
Revive Therapeutics Announces Strategic Expansion of Bucillamine Program Across Infectious Diseases, Defence and Biothreat Medical Countermeasures
accessnewswire.com · May 20
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.